TBPH - Theravance Biopharma, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue60,37015,38648,64842,126
Cost of Revenue202,063179,917144,606133,822
Gross Profit-141,693-164,531-95,958-91,696
Operating Expenses
Research Development----
Selling General and Administrative97,05895,59284,50990,203
Non Recurring----
Others----
Total Operating Expenses299,121275,509229,115224,025
Operating Income or Loss-238,751-260,123-180,467-181,899
Income from Continuing Operations
Total Other Income/Expenses Net12,666-11,588-92831
Earnings Before Interest and Taxes-238,751-260,123-180,467-181,899
Interest Expense-10,482-8,547-1,404-1,404
Income Before Tax-226,085-271,711-180,559-181,268
Income Tax Expense-10,56113,69410,110951
Minority Interest----
Net Income From Continuing Ops-215,524-285,405-190,669-182,219
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-215,524-285,405-190,669-182,219
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-215,524-285,405-190,669-182,219